<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602975</url>
  </required_header>
  <id_info>
    <org_study_id>2018-017</org_study_id>
    <nct_id>NCT04602975</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a</brief_title>
  <acronym>GlycoShig3</acronym>
  <official_title>A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill &amp; Melinda Gates Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry M. Jackson Foundation Medical Research International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinWin Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study among adults, children and infants in Kenya to determine if a new type of&#xD;
      glycoconjugate vaccine incorporating a synthetic carbohydrate component is safe and induces&#xD;
      immunity against Shigella.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to examine the safety and immunogenicity of two doses of the&#xD;
      parenteral synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a&#xD;
      (Shigella flexneri 2a-Tetanus Toxoid15 (SF2a-TT15)) adjuvanted or not with Alhydrogel in&#xD;
      infants in an endemic country (Kenya), the target population for the vaccine, using an&#xD;
      age-descending approach. In total, 232 participants will be enrolled in the study: 16 adults&#xD;
      (18-50 years-old), 16 children (2-5 years-old) and 200 infants (9 months-old +/ 1 mo).&#xD;
&#xD;
      The vaccine will be tested in adults first, then in children and eventually in infants in&#xD;
      Kenya (where Shigella infection is present), based on the safety/tolerability in each group&#xD;
      before to moving to the other. Participants will be randomly assigned to receive the study&#xD;
      vaccine or a placebo control (same solution but without the vaccine component). The&#xD;
      participants will have to go through all the trial procedures including the 14 visits (3&#xD;
      injections and 11 follow-up) during a 16 months period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, age descending (3 cohorts), with dose escalation in the target cohort</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Every team will be masked except the pharmacist.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number, proportion,severity and relatedness of adverse events (AEs) to measure the safety and tolerability of SF2a-TT15 vaccine (2 μg OS and 10 μg OS) in each cohort.</measure>
    <time_frame>15 months</time_frame>
    <description>Solicited reactions, AEs, SAEs assessed post-vaccination using targeted physical examinations, vital signs, and clinical laboratory tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analyses of the serum anti-S. flexneri 2a lipopolysaccharide (LPS) IgG antibody response in the infant target population to assess the immunogenicity of the vaccine.</measure>
    <time_frame>15 months</time_frame>
    <description>Proportion of responders (4-fold increases over baseline) in serum anti-S. flexneri 2a LPS IgG antibody response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number and proportion of responders, the geometric mean titer (GMT), mean fold-rises (compared to baseline), and peak-post-vaccination of the serum bactericidal activity (SBA) antibody (functionality of SF2a-specific IgGs antibodies in infants).</measure>
    <time_frame>15 months</time_frame>
    <description>Proportion of responders (4-fold increases over baseline) in serum bactericidal activity (SBA) antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyses of the serum anti-S. flexneri 2a LPS Immunoglobulins G (IgG) antibody response in the adult and children cohorts.</measure>
    <time_frame>15 months</time_frame>
    <description>Proportion of responders (4-fold increases over baseline) in serum anti-S. flexneri 2a LPS IgG antibody response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Measle-Rubella (MR) vaccine immune response in SF2a-TT15 vaccinees and placebo groups for the infant cohort.</measure>
    <time_frame>15 months</time_frame>
    <description>The antibody titer to the MR vaccine will be compared between SF2a-TT15 vaccinees and placebo groups to assess whether the SF2a-TT15 Shigella vaccine candidate impacts on the immunogenicity of the MR vaccine.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Adults cohort 1 vaccinees</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 intramuscular (IM) injections with the 10μg OS adjuvanted dose (or matching placebo), at a ratio of 3:1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults cohort 1 placebo recipients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 IM injections with the adjuvanted matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children cohort 2 vaccinees</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the 10 μg OS dose with Alhydrogel (or matching placebo) at a ratio of 3:1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children cohort 2 placebo recipients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the matching placebo with Alhydrogel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants cohort 3A vaccinees (-)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants cohort 3A placebo recipients (-)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants cohort 3A vaccinees (+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants cohort 3A placebo recipients (+)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants cohort 3B vaccinees (-)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants cohort 3B placebo recipients (-)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants cohort 3B vaccinees (+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants cohort 3B placebo recipients (+)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection SF2A-TT15 10 µg Adjuvanted</intervention_name>
    <description>Intramuscular injection of experimental vaccine (adjuvanted 10 µg)</description>
    <arm_group_label>Adults cohort 1 vaccinees</arm_group_label>
    <arm_group_label>Children cohort 2 vaccinees</arm_group_label>
    <arm_group_label>Infants cohort 3B vaccinees (+)</arm_group_label>
    <other_name>SF2A-TT15 10 µg Adjuvanted</other_name>
    <other_name>Anti-shigella experimental vaccine (10µg with alhydrogel)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection SF2A-TT15 10 µg</intervention_name>
    <description>Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)</description>
    <arm_group_label>Infants cohort 3B vaccinees (-)</arm_group_label>
    <other_name>SF2A-TT15 10 µg not adjuvanted</other_name>
    <other_name>Anti-shigella experimental vaccine (10µg without alhydrogel)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection Adjuvanted Placebo</intervention_name>
    <description>Intramuscular injection of Placebo with alhydrogel</description>
    <arm_group_label>Adults cohort 1 placebo recipients</arm_group_label>
    <arm_group_label>Children cohort 2 placebo recipients</arm_group_label>
    <arm_group_label>Infants cohort 3A placebo recipients (+)</arm_group_label>
    <arm_group_label>Infants cohort 3B placebo recipients (+)</arm_group_label>
    <other_name>Placebo with Alhydrogel injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection Placebo</intervention_name>
    <description>Intramuscular injection of the not adjuvanted Placebo</description>
    <arm_group_label>Infants cohort 3A placebo recipients (-)</arm_group_label>
    <arm_group_label>Infants cohort 3B placebo recipients (-)</arm_group_label>
    <other_name>Placebo without alhydrogel injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection SF2A-TT15 2 µg Adjuvanted</intervention_name>
    <description>Intramuscular injection of experimental vaccine (adjuvanted 2 µg)</description>
    <arm_group_label>Infants cohort 3A vaccinees (+)</arm_group_label>
    <other_name>SF2A-TT15 2 µg Adjuvanted</other_name>
    <other_name>Anti-shigella experimental vaccine (2µg with alhydrogel)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection SF2A-TT15 2 µg</intervention_name>
    <description>Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)</description>
    <arm_group_label>Infants cohort 3A vaccinees (-)</arm_group_label>
    <other_name>SF2A-TT15 2 µg not adjuvanted</other_name>
    <other_name>Anti-shigella experimental vaccine (2µg without alhydrogel)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For adults:&#xD;
&#xD;
          1. Healthy men and women between 18 and 50 (inclusive) years of age.&#xD;
&#xD;
          2. Subjects who provide written informed consent or thumb print in the presence of a&#xD;
             witness to participate in the study&#xD;
&#xD;
          3. Women willing to use at least 1 reliable method of contraception during the study&#xD;
             period, or are surgically sterilized, and agree to undergo repeated pregnancy tests&#xD;
             (before each vaccination) and men willing to use an effective method of contraception&#xD;
             (e.g. condom).&#xD;
&#xD;
        For children and infants:&#xD;
&#xD;
          1. Healthy boys and girls between 2 and 5 years of age for the children group (cohort 2)&#xD;
&#xD;
          2. Healthy boys and girls 9 mo-old (+/- 1 month) for the infant group (cohort 3)&#xD;
&#xD;
          3. Parents or legally acceptable representatives, as appropriate, who are willing and&#xD;
             able to provide signed/thumb printed informed consent for children and infants.&#xD;
&#xD;
          4. Infant and children should have a normal nutritional Z score (-2 or greater) according&#xD;
             to the mother and child health handbook of the republic of Kenya - Ministry of Health&#xD;
             before entering the trial.&#xD;
&#xD;
        For all:&#xD;
&#xD;
          1. Signed/thumb written informed consent, in accordance with local practice, provided by&#xD;
             adult volunteers (participants 18 years of age and older), parent(s) or legal&#xD;
             representative(s) for children and infants participants as applicable, who, in the&#xD;
             opinion of the Investigator, can and will comply with the requirements of the&#xD;
             protocol.&#xD;
&#xD;
          2. Subjects in general good health in the opinion of the Investigator as determined by&#xD;
             medical history, vital signs and a physical examination.&#xD;
&#xD;
          3. No clinically significant abnormalities in hematology, blood chemistry, or urinalysis&#xD;
             laboratory tests at screening.&#xD;
&#xD;
          4. Negative HIV, Hepatitis B and Hepatitis C serology tests and malaria test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a history of clinically significant gastrointestinal disorders (e.g.&#xD;
             gastroesophageal reflux disease, peptic ulcer, celiac disease, inflammatory bowel&#xD;
             disease).&#xD;
&#xD;
          2. Individuals with immunosuppressive diseases or under immunosuppressive therapy.&#xD;
&#xD;
          3. Previous participation in any study in which a Shigella-vaccine candidate was&#xD;
             administered.&#xD;
&#xD;
          4. Suspected or known hypersensitivity (including allergy) to any of the vaccine&#xD;
             components or to previous vaccine, or to medicinal products or medical equipment whose&#xD;
             use is foreseen in this study.&#xD;
&#xD;
          5. Use of any prescription or over-the-counter (OTC) medications, within 14 days prior&#xD;
             vaccination. Paracetamol or ibuprofen for symptomatic relief of pain is allowed until&#xD;
             48 hours prior to vaccination.&#xD;
&#xD;
          6. Women who are pregnant, breast-feeding, or are of childbearing age and are not on or&#xD;
             do not plan to use acceptable contraceptives for the duration of the study.&#xD;
&#xD;
          7. Subjects with any significant acute medical situation (e.g. acute infection) within 48&#xD;
             hrs prior to study entry, in the opinion of the Principal Investigator.&#xD;
&#xD;
          8. Participation in another clinical trial with drugs within 3 months prior first study&#xD;
             injection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armelle Phalipon, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Pasteur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence Mulard, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Pasteur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christiane Gerke, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Pasteur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fredrick Sawe, MBChB MMED</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya Medical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert W. Kaminski, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Walter Reed Army Institute of Research (WRAIR)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armelle Phalipon, PhD</last_name>
    <phone>1 40 61 32 46</phone>
    <phone_ext>0033</phone_ext>
    <email>armelle.phalipon@pasteur.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Souhir Neffati, Ms</last_name>
    <phone>1 44 38 93 51</phone>
    <phone_ext>0033</phone_ext>
    <email>souhir.neffati@pasteur.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KEMRI / Henry M. Jackson Foundation Medical Research International</name>
      <address>
        <city>Kericho</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrick SAWE, MD</last_name>
      <phone>+254 522 030 686</phone>
    </contact>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>anti-shigella</keyword>
  <keyword>shigella</keyword>
  <keyword>diarrheic disease</keyword>
  <keyword>Kenya</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This study is a part of a development program, Data will stay confidential and possibly shared only with program partners.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

